Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50-Day Moving Average of $4.43

Capricor Therapeutics Inc (NASDAQ:CAPR) shares passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $4.43 and traded as high as $4.89. Capricor Therapeutics shares last traded at $4.79, with a volume of 122,365 shares trading hands.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. StockNews.com lowered Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. Oppenheimer began coverage on Capricor Therapeutics in a research report on Friday, May 17th. They issued an “outperform” rating and a $14.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 target price on shares of Capricor Therapeutics in a report on Tuesday, May 14th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Capricor Therapeutics in a report on Tuesday, July 2nd. Finally, LADENBURG THALM/SH SH boosted their price objective on shares of Capricor Therapeutics from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, May 14th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.75.

Capricor Therapeutics Trading Down 2.1 %

The company has a market cap of $153.02 million, a P/E ratio of -5.50 and a beta of 4.00. The business has a 50 day moving average price of $4.43 and a 200-day moving average price of $5.13.

Institutional Trading of Capricor Therapeutics

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after purchasing an additional 200,499 shares during the period. Jump Financial LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $258,000. BNP Paribas Financial Markets bought a new stake in Capricor Therapeutics in the 1st quarter valued at $40,000. Marshall Wace LLP acquired a new stake in Capricor Therapeutics during the 2nd quarter valued at $426,000. Finally, Renaissance Technologies LLC boosted its position in Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 84,350 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.